Evidence map›Paper›PMID 40898705›Full record

Observational studyEpidemiology and infection2025

A retrospective global study of the prevalence of O-serotypes of invasive

Jeroen Geurtsen, Joachim Doua, Luis Martinez-Martinez, Patricia Ibarra de Palacios, Jeff Powis, Matthew Sims, Peter Hermans, Olivier Barraud, Philippe Lanotte, Joshua Thaden and 9 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in Epidemiology and infection, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Jeroen GeurtsenBacterial Vaccines Discovery and Early Development, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.ORCID https://orcid.org/0000-0002-8234-846X
Joachim DouaJanssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica, Beerse, Belgium at the time of analysis.
Luis Martinez-MartinezMicrobiology Unit, University Hospital Reina Sofia, Córdoba, Spain.
Patricia Ibarra de PalaciosClinical Development, Janssen Research & Development, Bern, Switzerland at the time of analysis.
Jeff PowisDepartment of Medicine, University of Toronto, Toronto, ON, Canada.
Matthew SimsDepartment Internal Medicine, Section of Infectious Diseases and International Medicine, Corewell Health William Beaumont University Hospital, Royal Oak, MI, USA.
Peter HermansJulius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands.
Olivier BarraudDepartment of Bacteriology, https://ror.org/01tc2d264CHU Limoges, Limoges, France.
Philippe LanotteDepartment of Bacteriology and Department of Microbiology, Bretonneau Hospital Tours University, University of Tours-INRAE, Tours, France.
Joshua ThadenDepartment of Medicine, https://ror.org/00py81415Duke University School of Medicine, Durham, NC, USA.
Oscar GoJanssen Research & Development, Raritan, NJ, USA.
Bart SpiessensJanssen Research & Development, Infectious Diseases & Vaccines, Janssen Pharmaceutica, Beerse, Belgium at the time of analysis.
Darren AbbanatJanssen Research & Development, Raritan, NJ, USA at the time of analysis.
Florian WagenlehnerDepartment of Urology, Pediatric Urology and Andrology, Justus-Liebig University, Giessen, Germany.
Tetsuya MatsumotoDepartment of Infectious Diseases, International University of Health and Welfare, Chiba, Japan.
Marc BontenJulius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, The Netherlands.
Michal SarneckiClinical Development, Janssen Vaccines, Bern, Switzerland at the time of analysis.
Jan PoolmanBacterial Vaccines Discovery and Early Development, Janssen Vaccines & Prevention B.V., Leiden, The Netherlands.
BAC0006 Study Group as instructed by the Study Steering Committee

Funding

Janssen Research and Development
6 · The paper itself

Abstract

Invasive

Indexed as

Escherichia coliEscherichia coli InfectionsO AntigensAdolescentAdultAgedAged, 80 and overFemaleHumansMaleMiddle AgedPrevalenceRetrospective StudiesSerogroupTertiary Care CentersYoung AdultO AntigensE. coliEXPEC9Vinvasive E. coli diseaseO-serotypevaccine

Identifiers

PMID40898705
PMCPMC12529432

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.